TY  - JOUR
AU  - Valverde, Araceli
AU  - Peñarando, Jon
AU  - Cañas, Amanda
AU  - López-Sánchez, Laura M
AU  - Conde, Francisco
AU  - Guil-Luna, Silvia
AU  - Hernández, Vanessa
AU  - Villar, Carlos
AU  - Morales-Estévez, Cristina
AU  - de la Haba-Rodríguez, Juan
AU  - Aranda, Enrique
AU  - Rodríguez-Ariza, Antonio
PY  - 2017
DO  - 10.18632/oncotarget.15567
UR  - https://hdl.handle.net/10668/25128
T2  - Oncotarget
AB  - Here we showed that the addition of the COX-2 inhibitor celecoxib improved the antitumor efficacy in colorectal cancer (CRC) of the monoclonal anti-EGFR antibody cetuximab. The addition of celecoxib augmented the efficacy of cetuximab to inhibit cell...
LA  - en
KW  - COX-2
KW  - EGFR
KW  - FOXM1
KW  - colorectal cancer
KW  - β-catenin
KW  - Adenocarcinoma
KW  - Animals
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Blotting, Western
KW  - Celecoxib
KW  - Cetuximab
KW  - Colorectal Neoplasms
KW  - Drug Synergism
KW  - ErbB Receptors
KW  - Fluorescent Antibody Technique
KW  - Forkhead Box Protein M1
KW  - Humans
KW  - Immunohistochemistry
KW  - Mice
KW  - Mice, Inbred NOD
KW  - Mice, SCID
KW  - Microscopy, Confocal
KW  - Signal Transduction
KW  - Xenograft Model Antitumor Assays
KW  - beta Catenin
KW  - ras Proteins
TI  - The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis.
TY  - research article
VL  - 8
ER  -